Advertisement


Anand P. Jillella, MD, on Acute Promyelocytic Leukemia: A Simplified Patient Care Strategy to Decrease Early Deaths

2022 ASH Annual Meeting and Exposition

Advertisement

Anand P. Jillella, MD, of Georgia Cancer Center at Augusta University, discusses results from the ECOG-ACRIN EA9131 Trial, which showed that using a simplified treatment algorithm and management recommendations made by a group of specialists, resulted in a dramatic improvement in 1-year survival of patients with acute promyelocytic leukemia (Abstract 421).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Acute promyelocytic leukemia is a highly aggressive but very curable leukemia. The current standard of care is all-trans retinoic acid and arsenic trioxide with or without chemotherapy. In clinical trials, about 95% to 98% of patients are cured. The induction death or early death, which is death within the first 30 days after diagnosis, is under 5%, and the relapse rate is less than 2%. So virtually everyone who survives induction is cured of their leukemia. However, that is not the case in the general population because in clinical trials the patients are usually younger and do not have any comorbid conditions. Whereas in the general population, you have older patients who might have other health issues. About 30% of patients do not survive induction or die during the first month after diagnosis. The one-year survival among all comers is about 60% to 70%. The only way to decrease survival among the general population is to decrease early deaths. The purpose of the ECOG-ACRIN 9131 trial was to decrease the induction mortality from an estimated 30% to less than 15%. At the Medical College of Georgia, in Augusta, Georgia, we recognized this as a problem way back in 2009. We evaluated our own experience and realized that 37% of our patients died within the first month after diagnosis. So we critically analyzed the problem and came up with a plan to decrease early deaths. Number one, we wrote a treatment algorithm or an operating procedure, which is a simplified procedure that tells you exactly how you have to manage the patient and the complications. The second thing is it is a rare disease, so we set up a panel of four experts. If there was a patient with APL in the community, the community oncologist would call one of the experts. The expert and the community oncologist would determine a consensus treatment plan, and the patient would be treated locally in the community but with ongoing communication with the APL expert. In this pilot trial, we accrued 120 patients. We had an early death rate of 8.5%. We used a similar model in the ECOG-ACRIN 9131 trial. We used the same algorithm. We set up seven APL experts who were available 24/7, and we rolled it out nationwide. There were absolutely no exclusion criteria. Elderly patients or patients with other health issues were recruited into the trial. A total of 200 patients were accrued, and we had seven deaths, which is an early death rate of 3.5%. As best as I know, this is the only proven concept that decreases early deaths in APL. This concept has also been proven in Latin America. The next steps would be to find a way to scale this and find a sustainable way to implement this nationwide.

Related Videos

Leukemia
Genomics/Genetics

Irene Roberts, MD, on Leukemogenesis in Infants With Trisomy 21

Irene Roberts, MD, of Oxford’s Weatherall Institute of Molecular Medicine, discusses children with Down syndrome, who have a more than 100-fold increased risk of developing acute myeloid leukemia before their fourth birthday compared to children without Down syndrome. Their risk of acute lymphoblastic leukemia is also increased by around 30-fold. Dr. Roberts details current knowledge about the biologic and molecular basis of this relationship between leukemia and Down syndrome, the role of trisomy 21 in leukemogenesis, and the clinical implications of these findings.

Lymphoma

Tomohiro Aoki, MD, PhD, on the Spatial Tumor Microenvironment and Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma

Tomohiro Aoki, MD, PhD, of the University of British Columbia and the Centre for Lymphoid Cancer at BC Cancer, discusses a novel prognostic model applicable to patients with relapsed or refractory classical Hodgkin lymphoma who were treated with autologous stem cell transplantation. The model has shown the interaction between the biomarker CXCR5 on HRS cells (Hodgkin and Reed/Sternberg cells, hallmarks of Hodgkin lymphoma) with specific follicular T helper cells and macrophages, a prominent crosstalk axis in relapsed disease. This insight opens new avenues to developing predictive biomarkers (Abstract 71).

 

Leukemia

Andrew Matthews, MD, on AML: Real-World Effectiveness of 7 + 3 Intensive Chemotherapy vs Venetoclax and a Hypomethylating Agent

Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a large, multicenter study that showed superior outcomes with 7 + 3 chemotherapy (cytarabine continuously for 7 days, along with short infusions of an anthracycline on each of the first 3 days) vs venetoclax in patients with acute myeloid leukemia (AML). In this real-world data set, the 7 + 3 cohort outperformed historical benchmarks in overall survival and early mortality, perhaps reflecting improved later lines of therapy and patient selection. Prospective studies (such as NCT04801797) must confirm the superiority of intensive chemotherapy (Abstract 426).

 

Multiple Myeloma
Immunotherapy

Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses Fc-mediated antibody effector function, inflammation resolution, and oligoclonality and their role in predicting sustained measurable residual disease negativity in patients with newly diagnosed multiple myeloma who were treated with immunotherapy regimens. For the first time, an analysis of T-cell receptors shows that oligoclonal profiles seen on treatment may influence the fitness of the immune response (Abstract 100).

Lymphoma
Immunotherapy

Tycel J. Phillips, MD, on Mantle Cell Lymphoma: New Findings on Glofitamab Monotherapy

Tycel J. Phillips, MD, of the City of Hope National Medical Center, discusses data that showed fixed-duration glofitamab monotherapy induced high and durable complete response rates in patients with mantle cell lymphoma (MCL) who received obinutuzumab pretreatment. This is one of the largest data sets and longest follow-ups reported with a CD20/CD3 bispecific monoclonal antibody for patients with relapsed or refractory MCL (Abstract 74).

Advertisement

Advertisement




Advertisement